Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease - Wikidata - awgldk - TriplyDB

Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease

Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease

http://www.wikidata.org/entity/Q33769790

about

Sanfilippo syndrome: causes, consequences, and treatments Ataxia is the major neuropathological finding in arylsulfatase G-deficient mice: similarities and dissimilarities to Sanfilippo disease (mucopolysaccharidosis type III).Female mucopolysaccharidosis IIIA mice exhibit hyperactivity and a reduced sense of danger in the open field test Hematopoietic stem cell and gene therapy corrects primary neuropathology and behavior in mucopolysaccharidosis IIIA mice.Myeloid/Microglial driven autologous hematopoietic stem cell gene therapy corrects a neuronopathic lysosomal disease The phytoestrogen genistein modulates lysosomal metabolism and transcription factor EB (TFEB) activation Recommendations on clinical trial design for treatment of Mucopolysaccharidosis Type III.Defects in the medial entorhinal cortex and dentate gyrus in the mouse model of Sanfilippo syndrome type B.Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB Effects of flavonoids on glycosaminoglycan synthesis: implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses.Cognitive development in patients with Mucopolysaccharidosis type III (Sanfilippo syndrome).Modulation of expression of genes involved in glycosaminoglycan metabolism and lysosome biogenesis by flavonoids.Estrogen receptor agonists for attenuation of neuroinflammation and neurodegeneration.Bilateral single-site intracerebral injection of a nonpathogenic herpes simplex virus-1 vector decreases anxiogenic behavior in MPS VII mice.Adverse Effects of Genistein in a Mucopolysaccharidosis Type I Mouse Model Synthetic genistein derivatives as modulators of glycosaminoglycan storage.A genetic model of substrate reduction therapy for mucopolysaccharidosis.The use of elevated doses of genistein-rich soy extract in the gene expression-targeted isoflavone therapy for Sanfilippo disease patients.Two-year follow-up of Sanfilippo Disease patients treated with a genistein-rich isoflavone extract: assessment of effects on cognitive functions and general status of patients Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder.Residual N-acetyl-α-glucosaminidase activity in fibroblasts correlates with disease severity in patients with mucopolysaccharidosis type IIIB Glycan-based biomarkers for mucopolysaccharidoses.The natural dietary genistein boosts bacteriophage-mediated cancer cell killing by improving phage-targeted tumor cell transduction.Factors and processes modulating phenotypes in neuronopathic lysosomal storage diseases.Emerging therapies for neurodegenerative lysosomal storage disorders - from concept to reality.Gene expression-targeted isoflavone therapy.Putative biological mechanisms of efficiency of substrate reduction therapies for mucopolysaccharidoses.Treatment options for lysosomal storage disorders: developing insights.Blood-brain barrier structure and function and the challenges for CNS drug delivery.Current and potential therapeutic strategies for mucopolysaccharidoses.Emerging drugs for the treatment of mucopolysaccharidoses.Genistein increases glycosaminoglycan levels in mucopolysaccharidosis type I cell models.Drug-Mediated Regulation of Glycosaminoglycan Biosynthesis.Beta amyloid peptide (25-35) leading to inflammation through Toll-like receptors and the anti-inflammatory effect of genistein in BV-2 cells.Busulfan conditioning enhances engraftment of hematopoietic donor-derived cells in the brain compared with irradiation.Substrate Deprivation Therapy to Reduce Glycosaminoglycan Synthesis Improves Aspects of Neurological and Skeletal Pathology in MPS I Mice.Coutinho et al. Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders. Int. J. Mol. Sci. 2016, 17, 1065.Hyperactive behaviour in the mouse model of mucopolysaccharidosis IIIB in the open field and home cage environments.How close are we to therapies for Sanfilippo disease?Macrophage enzyme and reduced inflammation drive brain correction of mucopolysaccharidosis IIIB by stem cell gene therapy.

P2860

Q26773200-B2B55C9D-5380-4D73-9125-D4DB99F1EDF6 Q27301077-C1CC6062-F0A9-41D4-B098-6A03222FCAD4 Q27317299-58CB2558-3F40-4B57-8ADD-F0CA356855B1 Q30524212-295409CC-D278-4A1C-BD6A-39A6B0A7AA04 Q30554347-E5843459-0431-405F-8ABE-749EDD747720 Q33761283-D6C91CD4-C1F9-4D05-9A91-24814ED828DC Q33837598-9B09E756-17B3-4546-90A5-239D4F322BE8 Q34077919-90524B6C-720D-409E-AADC-A53AA3955DA3 Q34256752-202B8C29-AE8D-4BE3-BE02-327A9FCDF7A1 Q34626878-459043C4-0D44-4113-94A4-3E36669F9BB1 Q35089081-D3E966E2-E47F-4D84-9D52-3EAA6C4DA979 Q35206289-E7799116-5BDF-4450-8F50-08258D32F4E4 Q35230714-F7A9A8F4-6E5A-4BE1-AA51-5BF02595E886 Q35664978-B8BE5D36-6C1E-4F53-9049-985FAE166C77 Q35795405-D5E895C4-8162-425A-8D37-B7C4B7E7786B Q36232973-ED9E9B49-7558-481D-9C9D-A1B7217426A4 Q36332885-4410B778-CB48-4CB4-B901-870CAD6293E3 Q36433464-41EF222D-1F30-42DE-952A-2A454E9BE3ED Q36516376-66CDF123-7E51-4F1C-B9D8-3ADE2D0A4D33 Q36844479-FDFF3717-332E-4BC8-B51C-51B003FB74DB Q36853478-B05F9279-FE3E-4AA0-8811-616F14E11927 Q37161285-E49B6A55-011F-40F5-81B4-98B934E2D319 Q37588421-60CD29B9-0582-49F3-9E79-2A7AF08122F1 Q37595934-6ABC9EB0-7F83-4CA0-9843-0F258260FAFB Q37876354-D968B154-0F92-41B6-B5FE-ADE840083C67 Q37987877-3C6E39A9-8652-4F01-AAA3-533FCCFB26ED Q38040710-89D8A628-A3EB-4500-BB74-70239D5802FD Q38046227-14560FD5-184F-4D30-98D6-F2BFDC2B7624 Q38100970-40102F04-9469-4587-B84F-0B398949EEFD Q38194635-F0AA35EC-351A-4514-B24E-9B8F30F53C64 Q38691996-167AA26B-C144-47A5-8923-CBFD975C9A3A Q39008165-FDEF60DF-B3C3-4349-A5EF-0D1303206F2C Q39060517-EA0422C5-CE0D-4247-B579-D6213C5AD3E8 Q39109759-7BE22193-245F-49A9-AC15-F64C196D4110 Q39590754-BC2B6264-9B51-48C6-AD89-76E8C82ABA0C Q41969965-79CBED0A-80A6-4042-A2E6-2BA93AC90E68 Q42323200-D6ABE8F7-320E-47A4-9DDD-C4BF32E8D79C Q42603418-3D4F1B1B-4653-4B97-998C-654426144E04 Q45872078-BCC71B20-13C1-4178-986C-E36740098A43 Q45875162-0F6E4EDB-9399-4081-85B3-B2D20749BDDA

P2860

Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease

http://www.wikidata.org/entity/Q33769790

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Genistein improves neuropathol ...... degenerative metabolic disease

@ast

Genistein improves neuropathol ...... degenerative metabolic disease

@en

type

label

Genistein improves neuropathol ...... degenerative metabolic disease

@ast

Genistein improves neuropathol ...... degenerative metabolic disease

@en

prefLabel

Genistein improves neuropathol ...... degenerative metabolic disease

@ast

Genistein improves neuropathol ...... degenerative metabolic disease

@en

P1433

Q33769790-91A96715-B507-4598-A4E9-614AD8A37228

P1476

Q33769790-67E5E940-B24E-4566-9DAF-15D01971CD53

P2093

Q33769790-07699AED-B05F-48CA-8BA9-38701030E4EB

Q33769790-47EA8C6D-6C42-45CA-A250-5F1B6F6E1F06

Q33769790-547A94D7-5FF7-41E1-9E2B-A668ECB68577

Q33769790-5E2815FB-B47E-4740-B2F2-43374D9FEAC6

Q33769790-81CC87FB-FEE4-4A95-8C45-3A099F8A73E4

Q33769790-868B2AC6-CF0F-4059-A819-60A690B612A1

Q33769790-DF29E99A-19AE-4066-8925-301939F607D8

Q33769790-DF8959DA-CFAF-491E-8E50-006491FD8AC4

P2860

Q33769790-038C9607-A738-43D0-8949-91AEDD79B3B5

Q33769790-19C16B0E-B766-4256-BDFC-83347988AF8C

Q33769790-225B38DF-E434-41B6-B57E-494625823A3F

Q33769790-293C8FF8-B286-485C-AA9D-FC3D71C41DAA

Q33769790-2BE00ECE-34E8-4C02-897E-AB3E469996D1

Q33769790-2C0E22B7-CEE7-4B62-8813-9BB459BA35AC

Q33769790-3911A97B-958F-45B8-BBA9-C10A77BAD0FB

Q33769790-3F169258-ADB3-4BB3-B12D-850461AE2FEA

Q33769790-4433A9AB-6E75-40DC-B902-2930AF33ED3E

Q33769790-4FCA2AE3-E8FB-4A79-A6C9-731BAFE2B3C4

P304

Q33769790-E58A3D19-3760-4838-BEF6-033D671C09D3

P31

Q33769790-713A8335-7544-487D-A1A0-B576616905D5

P356

Q33769790-386A93EF-2D8C-43AF-BCD6-CC9E78E2F7A4

P407

Q33769790-8CC4DD38-F1EB-4713-8F75-4A109A18049A

P433

Q33769790-300D0AF0-32A1-4087-95E4-07675AB867A9

P478

Q33769790-78C6EAB8-16AB-4B50-9573-46A697E94F27

P50

Q33769790-8A5C8453-4566-4D6F-BC32-2C7E406055BD

Q33769790-9641DB96-AE25-4E13-A23A-A80D585BC8EE

Q33769790-B1034118-62A8-48C8-9300-83C7CBD78BAB

Q33769790-BC028751-0AB4-4796-B1A6-A6E128BB1C89

P577

Q33769790-C464E1AE-BBAA-43F0-B032-ECAE12492FB7

P5875

Q33769790-6FFD843A-0AC7-4B85-8C21-63FE37F016EC

P698

Q33769790-77882F07-A279-416B-B22F-4EA92EF1EDB5

P921

Q33769790-6113A856-2751-44DB-B1EF-330C5207922E

P932

Q33769790-0D2766E6-4F5B-4011-BF9A-BE02CDD224D7

P356

JOURNAL.PONE.0014192

P1433

P1476

Genistein improves neuropathol ...... degenerative metabolic disease

@en

P2093

Brett E Crawford

http://www.w3.org/2001/XMLSchema#string

Fiona L Wilkinson

http://www.w3.org/2001/XMLSchema#string

Grzegorz Grynkiewicz

http://www.w3.org/2001/XMLSchema#string

J Ed Wraith

http://www.w3.org/2001/XMLSchema#string

Jillian R Brown

http://www.w3.org/2001/XMLSchema#string

Kia J Langford-Smith

http://www.w3.org/2001/XMLSchema#string

Marie T Vanier

http://www.w3.org/2001/XMLSchema#string

Rob F Wynn

http://www.w3.org/2001/XMLSchema#string

P2860

Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding alpha-N-acetylglucosaminidase

NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin

SNARE function analyzed in synaptobrevin/VAMP knockout mice

Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses

Early neurodegeneration progresses independently of microglial activation by heparan sulfate in the brain of mucopolysaccharidosis IIIB mice

Genistein, a specific inhibitor of tyrosine-specific protein kinases

The frequency of lysosomal storage diseases in The Netherlands.

Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice.

Lysosomal disorders.

Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB

P304

e14192

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0014192

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Alex Langford-smith

Marcelina Malinowska

Grzegorz Węgrzyn

P577

2010-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49677709

http://www.w3.org/2001/XMLSchema#string

P698

21152017

http://www.w3.org/2001/XMLSchema#string

P921

neurodegeneration

P932

2995736

http://www.w3.org/2001/XMLSchema#string